Therapeutic value of trimetazidine in patients with coronary heart disease and left ventricular dysfunction

WANG Cheng,WANG Linguang,JIANG Shuzhong,ZHANG Yigang,FENG Chunguang,ZONG Xuefeng,ZHU Ke,FU Qiang,QIAO Weili
DOI: https://doi.org/10.3969/j.issn.1674-4721.2009.25.004
2009-01-01
Abstract:Objective:To assess the effect and the safety of trimetazidine on the treatment of patients with coronary heart disease and left ventricular dysfunction. Methods:64 patients with coronary heart disease and left ventricular dysfunction were enrolled in this clinical trial and was divided into treatment group(n=33) and control group(n=31) . The treatment group received TMZ(20 mg,3 times per day) for 12 months addition to conventional therapy. Patients were followed up for 12 months and assessments included clinical evaluation,electrocardiography,echocardiography,Holter and 6 minutes walk distance. Results:All patients tolerated 60 mg of trimetazidine for 12 months,left ventricular ejection fraction(LVEF) was increased from(31.6±7.5) % to(40.7±9.8) %(P<0.01) . Left ventricular end-diastolic volume(LVEDV) was decreased from(58.5±6.8) ml/m2 to(52.1±7.7) ml/m2(P<0.01) . The cardio-thorax ratio was decreased from(57.2±5.6) % to(53.0±6.9) %(P< 0.01) . Attacks of angina recorded by Holter was decreased from(3.6±4.8) to(1.2±3.4) (P<0.01) . 6 minutes walk distance was increased from(134.8±47.1) m to(340.9±56.5) m(P<0.01) . Conclusion:Trimetazidine seems to improve clinical status,ejection fraction and 6 minutes walk distance,and reduce angina onsets,LVEDV,without adverse effects in patients with ischemic cardiomyopathy.
What problem does this paper attempt to address?